LOTUS EDGE
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $464.64 | 33 | 9 |
| 2020 | $840,145 | 703 | 317 |
| 2019 | $322,400 | 580 | 289 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $688,361 | 104 | 59.2% |
| Unspecified | $283,687 | 7 | 24.4% |
| Travel and Lodging | $83,627 | 247 | 7.2% |
| Consulting Fee | $55,975 | 20 | 4.8% |
| Food and Beverage | $49,359 | 937 | 4.2% |
| Space rental or facility fees (teaching hospital only) | $2,000 | 1 | 0.2% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Low Risk TAVR Feasibility of Transcatheter Aortic Valve Replacement in Low Risk Patients with Symptomatic Severe Aortic Stenosis | BOSTON SCIENTIFIC CORPORATION | $200,000 | 0 |
| Lotus Edge In TAVR A Novel Implant Technique to Minimize Incidence of Post Operative Pacemaker | BOSTON SCIENTIFIC CORPORATION | $52,000 | 0 |
| MANAGE TAVR Database MANAGEment of Transcatheter Aortic Valve Therapy | BOSTON SCIENTIFIC CORPORATION | $20,000 | 0 |
| REPRISE IV | BOSTON SCIENTIFIC CORPORATION | $11,687 | 2 |
Top Doctors Receiving Payments for LOTUS EDGE — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Lexington, KY | $563.96 | 4 |
| , M.D | Cardiovascular Disease | Lexington, KY | $563.96 | 4 |
| , MD | Cardiovascular Disease | Lexington, KY | $563.96 | 4 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Lexington, KY | $563.96 | 4 |
| , M.D | Interventional Cardiology | Plano, TX | $562.50 | 1 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Kansas City, MO | $502.88 | 3 |
| , D.O | Internal Medicine | High Point, NC | $495.54 | 1 |
| , M.D | Cardiovascular Disease | Rome, GA | $470.00 | 3 |
| , MD | Cardiovascular Disease | Portland, OR | $401.15 | 3 |
| , MD | Interventional Cardiology | Ft Mitchell, KY | $396.86 | 4 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Annandale, VA | $375.00 | 1 |
| , M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Wynnewood, PA | $375.00 | 1 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Nashville, TN | $375.00 | 1 |
| , MD | Interventional Cardiology | Chandler, AZ | $347.64 | 3 |
| , M.D | Cardiovascular Disease | Sayre, PA | $324.03 | 2 |
| , MD | Cardiovascular Disease | Liverpool, NY | $316.45 | 3 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Syracuse, NY | $316.45 | 3 |
| , MD, FACC | Cardiovascular Disease | Englewood, NJ | $316.45 | 3 |
| , MD | Interventional Cardiology | Overland Park, KS | $301.90 | 3 |
| , MD | Interventional Cardiology | Saint Paul, MN | $300.55 | 8 |
| , MD | Cardiovascular Disease | Saint Louis, MO | $288.12 | 3 |
| , M.D | Cardiovascular Disease | Macon, GA | $281.01 | 4 |
| , M.D | Cardiovascular Disease | Houston, TX | $277.28 | 2 |
| , MD | Interventional Cardiology | Newtown, PA | $272.98 | 3 |
| , M.D | Cardiovascular Disease | Marietta, GA | $251.68 | 4 |
Manufacturing Companies
- Boston Scientific Corporation $878,789
- BOSTON SCIENTIFIC CORPORATION $284,220
Product Information
- Type Device
- Total Payments $1.2M
- Total Doctors 551
- Transactions 1,316
About LOTUS EDGE
LOTUS EDGE is a device associated with $1.2M in payments to 551 healthcare providers, recorded across 1,316 transactions in the CMS Open Payments database. The primary manufacturer is Boston Scientific Corporation.
Payment data is available from 2019 to 2021. In 2021, $464.64 was paid across 33 transactions to 9 doctors.
The most common payment nature for LOTUS EDGE is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($688,361, 59.2% of total).
LOTUS EDGE is associated with 4 research studies, including "Low Risk TAVR Feasibility of Transcatheter Aortic Valve Replacement in Low Risk Patients with Symptomatic Severe Aortic Stenosis" ($200,000).